Press Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease
First Precision and First Oral Medicine for Fabry Disease Approved for 348 Amenable GLA Variants Click to download. Click to download. Galafold is the First New Treatment Option for Fabry Disease in the U.S. in 15+ Years Amicus Therapeutics to Host Conference Call on August 13 at 8 a.m.
View HTML
Toggle Summary Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates
2Q18 Net Product Sales of $21.3M Driven by Galafold ® (Migalastat) Expansion Company Increases FY18 Global Galafold Revenue Guidance to $80M-$90M Pompe Clinical, Regulatory and Manufacturing Activities Continue to Advance Conference Call and Webcast Today at 8:30am ET CRANBURY, N.J. , Aug.
View HTML
Toggle Summary Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018
CRANBURY, N.J. , July 31, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 7, 2018 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2018 .
View HTML
Toggle Summary Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease
CRANBURY, N.J. , June 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for
View HTML
Toggle Summary Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors
Directors Donald J. Hayden, Jr. and Craig A. Wheeler Re-Elected CRANBURY, N.J. , June 08, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the
View HTML
Toggle Summary Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
CRANBURY, N.J. , June 01, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics , Inc. (Nasdaq:FOLD) announced today that John F. Crowley , Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 39th Annual Global Healthcare Conference
View HTML
Toggle Summary Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan
First Oral Precision Medicine for Fabry Patients with an Amenable Mutation Now Available in Japan CRANBURY, N.J. and TOKYO , May 30, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold ®
View HTML
Toggle Summary Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
CRANBURY, N.J. , May 09, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Tuesday, May 15,
View HTML
Toggle Summary Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
Continued Global Galafold ® (Migalastat) Adoption and Expansion – Reaffirms FY18 Revenue Guidance of $75M-$85M at Top End of Range Significant Momentum with Pompe Clinical, Regulatory and Manufacturing Activities - GMP Manufacturing Campaigns of ATB200 Drug Substance and Drug Product Completed at
View HTML
Toggle Summary Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
CRANBURY, N.J. , April 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2018 . The call will be hosted by John F.
View HTML